Inverse relationship between 15-lipoxygenase-2 and PPAR-γ gene expression in normal epithelia compared with tumor epithelia

Neoplasia

Volumn 7, Issue 3, 2005, Pages 280-293

  Subbarayan, Vemparala ^a   Xu, Xiao Chun ^a   Kim, Jeri ^a   Yang, Peiying ^a   Hoque, Ashraful ^a   Sabichi, Anita L ^a   Llansa, Norma ^a   Mendoza, Gabriella ^a   Logothetis, Christopher J ^a   Newman, Robert A ^a   Lippman, Scott M ^a   Menter, David G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

15 lipoxygenase; Gene expression; Peroxisome proliferator activated receptor ; PPAR ; Prostate cancer

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE 2; CELL NUCLEUS RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTON TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING; TANDEM MASS SPECTROMETRY; TISSUE CULTURE; TUMOR CELL CULTURE;

EID: 20144364754     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04457     Document Type: Article

References (73)

1. Gillmor SA, Villasenor A, Fletterick R, Sigal E, and Browner MF (1997). The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat Struct Biol 4, 1003-1009.
2. Prigge ST, Boyington JC, Faig M, Doctor KS, Gaffney BJ, and Amzel LM (1997). Structure and mechanism of lipoxygenases. Biochimie 79, 629-636.
3. Brash AR (1999). Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274, 23679-23682.
4. Jisaka M, Kim RB, Boeglin WE, and Brash AR (2000). Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2. J Biol Chem 275, 1287-1293.
5. Sigal E, Craik CS, Dixon RA, and Nadel JA (1989). Cloning and expression of human arachidonate 15-lipoxygenase. Trans Assoc Am Physicians 102, 176-184.
6. Brash AR, Boeglin WE, and Chang MS (1997). Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA 94, 6148-6152.
7. Kuhn H, Barnett J, Grunberger D, Baecker P, Chow J, Nguyen B, Bursztyn-Pettegrew H, Chan H, and Sigal E (1993). Overexpression, purification and characterization of human recombinant 15-lipoxygenase. Biochim Biophys Acta 1169, 80-89.
8. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, et al. (2001). 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 61, 497-503.
9. Ricote M, Welch JS, and Glass CK (2000). Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. Horm Res 54, 275-280.
10. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, and Glass CK (1999). Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400, 378-382.
11. Nagy L, Tontonoz P, Alvarez JG, Chen H, and Evans RM (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93, 229-240.
12. Shappell SB, Boeglin WE, Olson SJ, Kasper S, and Brash AR (1999). 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155, 235-245.
13. Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, Liu J, Chandra J, Traag J, Klein RD, Fischer SM, et al. (2002). Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 277, 16189-16201.
14. Bhatia B, Maldonado CJ, Tang S, Chandra D, Klein RD, Chopra D, Shappell SB, Yang P, Newman RA, and Tang DG (2003). Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX-2) and its splice variants. J Biol Chem 278, 25091-25100.
15. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr, and Shappell SB (2000). Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31, 1146-1154.
16. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, and Menter DG (2001). Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 61, 2720-2726.
17. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, et al. (1997). The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272, 18779-18789.
18. Laborda J (1991). 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19, 3998.
19. Kempen EC, Yang P, Felix E, Madden T, and Newman RA (2001). Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem 297, 183-190.
20. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, and Lotan R (1994). Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 54, 3580-3587.
21. Tontonoz P, Hu E, Graves RA, Budavari AI, and Spiegelman BM (1994). mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8, 1224-1234.
22. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx W, Palinski W, and Glass CK (1998). Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95, 7614-7619.
23. Salas TR, Reddy SA, Clifford JL, Davis RJ, Kikuchi A, Lippman SM, and Menter DG (2003). Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 278, 41338-41346.
24. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, and Evans RM (1995). 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803-812.
25. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, and Glass CK (1997). Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 17, 2166-2176.
26. Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, Iyengar S, Tang DG, and Lippman SM (2003). Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 5, 121-127.
27. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, and Green S (1992). The mouse peroxisome proliferates activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11, 433-439.
28. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, and Menter DG (2004). Differential PPAR-γ isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomark Prev in press.
29. Krieg P, Marks F, and Furstenberger G (2001). A gene cluster encoding human epidermis-type lipoxygenases at chromosome 17p13.1: cloning, physical mapping, and expression. Genomics 73, 323-330.
30. Marom Z, Shelhamer JH, Sun F, and Kaliner M (1983). Human airway monohydroxyeicosatetraenoic acid generation and mucus release. J Clin Invest 72, 122-127.
31. Henke D, Danilowicz RM, Curtis JF, Boucher RC, and Eling TE (1988). Metabolism of arachidonic acid by human nasal and bronchial epithelial cells. Arch Biochem Biophys 267, 426-436.
32. Mattoli S, Mezzetti M, Fasoli A, Patalano F, and Allegra L (1990). Nedocromil sodium prevents the release of 15-hydroxyeicosatetraenoic acid from human bronchial epithelial cells exposed to toluene diisocyanate in vitro. Int Arch Allergy Appl Immunol 92, 16-22.
33. Vignola AM, Chanez P, Campbell AM, Bousquet J, Michel FB, and Godard P (1993). Functional and phenotypic characteristics of bronchial epithelial cells obtained by brushing from asthmatic and normal subjects. Allergy 48, 32-38 discussion 39-48.
34. Lazarus SC (1987). The role of mast cell-derived mediators in airway function. Am Rev Respir Dis 135, S35-S38.
35. Hafstrom I, Ringertz B, Palmblad J, and Malmsten C (1984). Effects of auranofin on leukotriene production and leukotriene stimulated neutrophil function. Agents Actions 15, 551-555.
36. Johnson HG, McNee ML, and Sun FF (1985). 15-Hydroxyeicosatetraenoic acid is a potent inflammatory mediator and agonist of canine tracheal mucus secretion. Am Rev Respir Dis 131, 917-922.
37. Jeffrey P and Zhu J (2002). Mucin-producing elements and inflammatory cells. Novartis Found Symp 248, 51-68 discussion 68-75, 277-282.
38. Profita M, Sala A, Siena L, Henson PM, Murphy RC, Paterno A, Bonanno A, Riccobono L, Mirabella A, Bonsignore G, et al. (2002). Leukotriene B4 production in human mononuclear phagocytes is modulated by interleukin-4-induced 15-lipoxygenase. J Pharmacol Exp Ther 300, 868-875.
39. Ternowitz T, Fogh K, and Kragballe K (1988). 15-Hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits LTB4-induced chemotaxis of human neutrophils. Skin Pharmacol 1, 93-99.
40. Blazquez M and Shennan KI (2000). Basic mechanisms of secretion: sorting into the regulated secretory pathway. Biochem Cell Biol 78, 181-191.
41. [41 ] Bankaitis VA and Morris AJ (2003). Lipids and the exocytotic machinery of eukaryotic cells. Curr Opin Cell Biol 15, 389-395.
42. Holthuis JC, van Meer G, and Huitema K (2003). Lipid microdomains, lipid translocation and the organization of intracellular membrane transport. Mol Membr Biol 20, 231-241 (Review).
43. Sleight RG and Abanto MN (1989). Differences in intracellular transport of a fluorescent phosphatidylcholine analog in established cell lines. J Cell Sci 93 (Part 2), 363-374.
44. Jiang WG, Douglas-Jones A, and Mansel RE (2003). Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fat Acids 69, 275-281.
45. Chu HW, Balzar S, Westcott JY, Trudeau JB, Sun Y, Conrad DJ, and Wenzel SE (2002). Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy 32, 1558-1565.
46. Bradding P, Redington AE, Djukanovic R, Conrad DJ, and Holgate ST (1995). 15-Lipoxygenase immunoreactivity in normal and in asthmatic airways. Am J Respir Crit Care Med 151, 1201-1204.
47. Nasser SM and Lee TH (2002). Products of 15-lipoxygenase: are they important in asthma? Clin Exp Allergy 32, 1540-1542.
48. Kumlin M, Ohlson E, Bjorck T, Hamberg M, Granstrom E, Dahlen B, Zetterstrom O, and Dahlen SE (1991). 15(S)-hydroxyeicosatetraenoic acid (15-HETE) is the major arachidonic acid metabolite in human bronchi. Adv Prostaglandin Thromboxane Leukotriene Res 21A, 441-444.
49. Moody TW, Leyton J, Martinez A, Hong S, Malkinson A, and Mulshine JL (1998). Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res 24, 617-628.
50. Kudryavtsev IA, Golenko OD, Gudkova MV, and Myasishcheva NV (2002). Arachidonic acid metabolism in growth control of A549 human lung adenocarcinoma cells. Biochemistry (Moscow) 67, 1021-1026.
51. Shappell SB, Keeney DS, Zhang J, Page R, Olson SJ, and Brash AR (2001). 15-Lipoxygenase-2 expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. J Invest Dermatol 117, 36-43.
52. Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta T, Tanaka T, Maruyama M, Katahira H, Yoshimoto K, et al. (2004). Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism 53, 488-494.
53. Yajima K, Hirose H, Fujita H, Seto Y, Ukeda K, Miyashita K, Kawai T, Yamamoto Y, Ogawa T, Yamada T, et al. (2003). Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 284, E966-E971.
54. Camejo G, Ljung B, and Oakes N (2001). Pharmacological treatment of insulin resistance in obesity. Nutr Metab Cardiovasc Dis 11, 275-284.
55. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, and Wahli W (1992). Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887.
56. Moller DE and Berger J (2002). The mechanisms of action of PPARs. Annu Rev Med 53, 409-435.
57. Flemmer M and Scott J (2001). Mechanism of action of thiazolidine-diones. Curr Opin Invest Drugs 2, 1564-1567.
58. Murphy GJ and Holder JC (2000). PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21, 469-474.
59. Kersten S, Desvergne B, and Wahli W (2000). Roles of PPARs in health and disease. Nature 405, 421-424.
60. Fujiwara T and Horikoshi H (2000). Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 67, 2405-2416.
61. Straus DS and Glass CK (2001). Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21, 185-210.
62. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, and Glass CK (2000). 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 97, 4844-4849.
63. Negishi M, Koizumi T, and Ichikawa A (1995). Biological actions of delta 12-prostaglandin J2. J Lipid Mediat Cell Signal 12, 443-448.
64. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, and Lazar MA (1995). Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270, 23975-23983.
65. Sun D and Funk CD (1996). Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. J Biol Chem 271, 24055-24062.
66. Wigren J, Surapureddi S, Olsson AG, Glass CK, Hammarstrom S, and Soderstrom M (2003). Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein. J Endocrinol 177, 207-214.
67. Hsi LC, Wilson L, Nixon J, and Eling TE (2001). 15-Lipoxygenase-1 metabolites down-regulate PPAR gamma via the MAP kinase signaling pathway. J Biol Chem 10, 10.
68. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris HZ, Fan HZ, Fischer SM, and Lippman SM (2003). The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 100, 9968-9973.
69. Shankaranarayanan P, Chaitidis P, Kuhn H, and Nigam S (2001). Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J Biol Chem 276, 42753-42760.
70. Kamitani H, Geller M, and Eling T (1998). Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 273, 21569-21577.
71. Kamitani H, Taniura S, Ikawa H, Watanabe T, Kelavkar UP, and Eling TE (2001). Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. Carcinogenesis 22, 187-191.
72. Spindler SA, Sarkar FH, Sakr WA, Blackburn ML, Bull AW, LaGattuta RG, and Reddy RG (1997). Production of 13-hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines. Biochem Biophys Res Commun 239, 775-781.
73. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, and Koeffler HP (1998). Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95, 8806-8811.